Search

High atomic number Z, nanoparticles are able to enhance the photoelectric and Compton effects under X-Ray irradiation resulting the increase of radiation therapy efficacy. To achieve enhanced radiation therapy, Bi2S3 biocompatible particles coated with bovine serum albumin (BSA) (Bi2S3@BSA HNPs) were prepared through a BSA-mediated biomineralization procedure under green conditions. Then, to achieve improved chemo-radiation therapy against HT-29 cancer cells, curcumin (CUR) as natural anti-cancer therapy agent loaded on the Bi2S3@BSA (Bi2S3@BSA@CUR HNPs). Next, this synthesized nanodrug was evaluated for physical and chemical properties and in vitro cytotoxicity studies. Here, in vitro enhanced chemo-radiation combination therapy power was evaluated against HT-29 cell line under 2 Gy and 6 Gy X-ray irradiation doses. The Bi2S3@BSA HNPs without irradiation rarely affect cell viability which shown the non-toxicity of Bi2S3@BSA HNPs. The result of this study proved that Bi2S3@BSA@CUR HNPs can be used as both proficient vehicles for effective delivery of CUR and radiosensitizer in the treatment of cancer. In addition, the result of this study confirmed that the combination of high Z-element nanoradiosensitizer, Bi2S3@BSA HNPs, with a natural anti-cancer drug, CUR, enhanced therapeutic power against HT-29 cells. [ABSTRACT FROM AUTHOR]

In this study we described the production of curcumin (CUR) loaded L‐tyrosine (Tyr coated Fe3O4 magnetic nanoparticles. CUR loaded Tyr modified Fe3O4 nanoparticles (F@Tyr@CUR NPs) were analyzed by transmission electron microscopy, fourier transform infrared spectroscopy, thermo gravimetric analysis, vibrating sample magnetometer, X‐ray diffraction and dynamic light scattering techniques. The dynamic light scattering results showed that the ζ‐potential of F@Tyr@CUR NPs was about −15.4 mV. Also, the internal average size was about 25.81 ± 3.31 (mean ± SD (n = 30)) nm. The drug loading and encapsulation efficiency were 8.87 ± 0.09% and 35.21 ± 0.41%, respectively. In addition, hemolysis test on human red blood cells were conducted to determine the hemocompatibility of F@Tyr@CUR NPs. Next, MTT assays on HEK‐293 were conducted to determine the toxicity of F@Tyr@CUR NPs. Lastly, the potential anticancer effect of F@Tyr@CUR NPs was considered on MCF‐7 cancer cell line. The outcomes indicated that these F@Tyr@CUR NPs are appropriate for delivery of CUR anticancer drug. Also, the MRI training established the effectiveness of Fe3O4 magnetic nanoparticles as contrast agent for the revealing of tumor as evidenced from the phantom images as well as higher T2 relaxivity. We have identified and developed a biocompatible drug delivery system (F@Tyr NPs), which could be used to delivery of chemotherapeutic agents such as CUR. Also, the MRI study demonstrated the effectiveness of Fe3O4 nanoparticles as contrast agent for the early detection of tumor as evidenced from the phantom images as well as higher T2 relaxivity. [ABSTRACT FROM AUTHOR]

This work described a folic acid conjugated delivery of chrysin-loaded bovine serum albumin nanoparticles, which could overcome the nonspecific targeting disadvantage. Chrysin (5, 7-dihydroxyflavone) is a natural flavonoid which have some significant biological effects on the processes of chemical defense. Chrysin loaded bovine serum albumin nanoparticles (Chrysin-BSA NPs) were synthesized by a simple desolvation procedure. Afterward, folic acid (FA) was conjugated to the surface of Chrysin-BSA NPs by carbodiimide chemistry (Chrysin-BSA-FA NPs). The resultant Chrysin-BSA-FA NPs showed a spherical shape, with a hydrodynamic diameter of 97.5 ± 5.8 nm (mean ± SD) nm and a ζ-potential of −11.3 mV. The in vitro drug release study of chrysin presented a sustained and controlled release pattern. Hemolysis assay and cytotoxicity study results on HFF-2 cell line show that as prepared BSA NPs are biocompatible. Both the Chrysin-BSA NPs and Chrysin-BSA-FA NPs prompted an enhanced cancer cell cytotoxic effect in contrast to chrysin solution. These data recommended that the folate-modified chrysin -loaded vehicle, which demonstrated better biocompatibility and potential superiority, could be a suitable cancer therapy in targeting tumors in the future. [ABSTRACT FROM AUTHOR]